Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy. - Wikidata - awgldk - TriplyDB

Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy.

Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy.

http://www.wikidata.org/entity/Q42997987

about

Prevention of Hepatitis B reactivation in the setting of immunosuppression Immunogenicity and mechanisms impairing the response to vaccines in inflammatory bowel disease Hepatitis B and C virus reactivation in immunosuppressed patients with inflammatory bowel disease What is the best way to manage screening for infections and vaccination of inflammatory bowel disease patients?Treatment of Hepatitis C in Patients Undergoing Immunosuppressive Drug Therapy Challenges in treating patients with inflammatory bowel disease and concurrent viral hepatitis infection.Management of ulcerative colitis in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease.Management of Crohn's disease in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease.Preventing infective complications in inflammatory bowel disease.Adverse events in IBD: to stop or continue immune suppressant and biologic treatment Vaccination and infection prevention in inflammatory bowel disease.Hepatitis B vaccination in patients with inflammatory bowel disease.Prevalence and influences of hepatitis B virus infection on inflammatory bowel disease: a retrospective study in southern China.Prevalence of hepatitis B and clinical outcomes in inflammatory bowel disease patients in a viral-endemic region.Vaccination issues in patients with inflammatory bowel disease receiving immunosuppression.Hepatobiliary manifestations in inflammatory bowel disease: the gut, the drugs and the liver.Suspected de novo Hepatitis B in a Patient Receiving Anti-Tumor Necrosis Factor Alpha Therapy for the Treatment of Crohn's Disease.Second Korean guidelines for the management of ulcerative colitis.Prevention and management of infectious complications in IBD.The influence of anti-TNF therapy on the course of chronic hepatitis C virus infection in patients with inflammatory bowel disease.Kinetic profiles and management of hepatitis B virus reactivation in patients with immune-mediated inflammatory diseases.Hepatitis B and inflammatory bowel disease: role of antiviral prophylaxis Approach and management of patients with chronic hepatitis B and C during the course of inflammatory bowel disease.Hepatitis B and immunosuppressive therapies for chronic inflammatory diseases: When and how to apply prophylaxis, with a special focus on corticosteroid therapy.Treatment of severe non-infectious uveitis in high-risk conditions (Part 2): systemic infections; management and safety issues.Emerging biologics in inflammatory bowel disease.Asymptomatic acute hepatitis E in a female patient with ulcerative colitis.The immunization status of patients with IBD is alarmingly poor before the introduction of specific guidelines.Treatment with infliximab or azathioprine negatively impact the efficacy of hepatitis B vaccine in inflammatory bowel disease patients.Reactivation of hepatitis B virus in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs.Detection of liver injury in IBD using transient elastography.Prevalence and factors related to hepatitis B and C infection in inflammatory bowel disease patients in China: a retrospective study.Optimizing screening for tuberculosis and hepatitis B prior to starting tumor necrosis factor-α inhibitors in Crohn's disease.CSH guidelines for the diagnosis and treatment of drug-induced liver injury Hepatitis B virus reactivation induced by infliximab administration in a patient with Crohn's disease.Prevalence and natural history of hepatitis B and C infections in a large population of IBD patients treated with anti-tumor necrosis factor-α agents.Effect of immunosuppressive therapy on patients with inflammatory bowel diseases and hepatitis B or C virus infection.Tumor necrosis factor inhibitor therapy for hepatitis B virus-infected individuals: How loud is the alarm bell?Hepatitis B virus reactivation in patients receiving cancer chemotherapy: natural history, pathogenesis, and management.Characteristics, Prevention, and Management of Hepatitis B Virus (HBV) Reactivation in HBV-Infected Patients Who Require Immunosuppressive Therapy.

P2860

Q26747023-F008B6CF-A9FD-4C99-8967-3AEBF0FF36AC Q26777330-E669A299-7381-4359-A2E2-2AD896C710B3 Q26827444-EA055473-6782-4C0E-87FC-25F5965EA38E Q27687191-DFE93644-5698-4EB8-BFD3-111C3E6E9C6A Q28073100-D2F1073E-3DF7-4A5B-B5AE-9BB6DBD91470 Q30244767-AF039C5F-ACDA-4487-8DD8-A99345A19993 Q33819473-B18934D1-7C3D-42C6-972B-754384BAFDBF Q33819478-9FB3E990-55D5-417A-8B61-9E499B5C7C72 Q34008766-3BD164A3-7881-479E-A09E-05A1491FF574 Q34073191-09B4B571-8B34-44AD-862B-2E116F90AB27 Q34389541-9FC6AD68-8E2A-437A-920F-B527B373FE91 Q34467285-15AC37EA-6726-4B2C-A45C-2697F2B8A953 Q35871046-F940ECB8-BD41-463F-935C-272DC2AB24DE Q36109460-F4E946A2-A18D-48F1-91B9-91CBEAB6117B Q36496958-B9A8775E-2EC0-4F67-AE8E-1704F0916595 Q37317444-9ACB3DA1-2266-4A9C-9874-023D6161C84E Q37603400-777E9D6F-5FD2-444D-8ABA-B84631A7D4BC Q37662503-4E97EB8B-E55E-45CB-BB14-9B0BFDFA8B08 Q38026405-039053B1-FAFA-437D-A99B-B920D1EA4A91 Q38062336-FB15C11B-A408-4C1F-B25B-7DB0AB1AA129 Q38084250-4CDA28D5-D2A9-4024-865F-135E2CBA97AD Q38094015-62A37C6F-626B-454B-8BB2-904710523F87 Q38235053-210A8C03-3B04-4495-A608-6F477200BB09 Q38408897-F273B7CC-E680-4F30-9365-60010E5156F7 Q38539281-4BDE5BC5-4852-4CA8-8228-D717876FB69B Q39004625-6F0B0381-D1AF-4C27-9E50-C681686CE492 Q40269137-86836F47-B3A0-4716-ACE5-39B18428FA42 Q40327479-9E99EB54-C252-4490-8897-F3E76A695C55 Q40946497-16B0CCC1-954F-4A4B-9AEC-7C36B38A53E6 Q42227093-54909B55-CF8B-4987-BCAC-8CADF2C817B6 Q42228367-861C87F3-C327-4F78-B308-BE9106747BF7 Q42267006-C699F4B9-2034-4B59-9F8F-54C53CDC939B Q42276425-33A513AF-D461-4CA1-A12C-A388525FEB28 Q42354312-41B2FC5E-F4F6-422B-8B2B-D19672E0E02E Q42959718-315D2795-BDB3-4A3E-ACD4-56179C3637D4 Q42978890-725BF664-A43A-4B28-BFD6-A60B818E6BE2 Q42988930-99C77E13-7663-4407-969E-19016A715B32 Q44736299-3F0A2079-A321-40E6-9450-C979857EBD47 Q45268408-18A5C291-B60F-49EF-B676-4FB4E8383035 Q45324587-2076DE4E-4347-4E19-801A-C5AA9CA8C196

P2860

Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy.

http://www.wikidata.org/entity/Q42997987

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

2010年學術文章

@zh-hant

name

Liver dysfunction related to h ...... ith immunosuppressive therapy.

@en

Liver dysfunction related to h ...... ith immunosuppressive therapy.

@nl

type

label

Liver dysfunction related to h ...... ith immunosuppressive therapy.

@en

Liver dysfunction related to h ...... ith immunosuppressive therapy.

@nl

prefLabel

Liver dysfunction related to h ...... ith immunosuppressive therapy.

@en

Liver dysfunction related to h ...... ith immunosuppressive therapy.

@nl

P1433

Q42997987-6A810A13-08E8-46E2-9E62-216197AF95F5

P1476

Q42997987-A770FB49-0521-4809-A884-7CC3ECE1D755

P2093

Q42997987-0126CEFB-936E-4E3B-B995-5EFF977EAAEB

Q42997987-0C92DAFD-2074-46EC-8139-7FF3E70B22F5

Q42997987-12E37A18-1277-47CD-A87A-39FB6BCFDDBE

Q42997987-140D92ED-490F-44E3-B9E9-D602DFCC48B8

Q42997987-23554856-96A1-4490-8E56-CA8A40F091C2

Q42997987-36D056CD-19D7-41C2-BE7B-50F45C608244

Q42997987-3B6C3D68-0B72-40C5-80EC-681DBD3EADE7

Q42997987-4057D09E-F68E-4A3F-8F3C-4052F7CCB09B

Q42997987-4FB48742-E6F8-4FE0-AE3C-A11BD09C574F

Q42997987-59F5875A-E01E-4BA4-9E6E-57F251F16A6A

P304

Q42997987-DDB9F4A2-74E6-4547-B999-3F336B9A124D

P31

Q42997987-565FF1AA-37D3-419A-ABA1-9420ACA236B0

P356

Q42997987-8330C6EB-D3BB-4DF8-AD28-63F83D67CF36

P407

Q42997987-C8F9D03A-F30D-4914-A4DA-1D5809C8A979

P433

Q42997987-CF6F185B-4668-4817-8732-3F5322B05654

P478

Q42997987-317B4BB2-2D14-46B5-94A2-9E7CDCCAC875

P50

Q42997987-02EC0C0D-8751-47F0-A417-AB40E4B16329

Q42997987-1DB87F6C-7416-45E0-A78C-81939AE6E52A

Q42997987-1F82C0E9-2DED-4DDF-81C5-98BF4EF5CB79

Q42997987-250FE9F5-2D64-4193-BC30-1A5E32001E5C

Q42997987-40BA3863-EDFB-4472-80E9-B8BF2B11C6CE

Q42997987-82C67404-6452-4CDA-AADB-2411CCE05729

Q42997987-8471052C-7E65-45C1-8CE1-04358F1241D4

Q42997987-89521156-27CB-48E9-9E22-AA08E6609C81

Q42997987-A0A959C1-8C60-4C12-9B41-F786DE198EF3

Q42997987-B730E0F7-34AC-47E1-8693-8185745C29A0

P577

Q42997987-A4FCC6DD-90FE-4B9D-97E1-79EF13D9FD31

P698

Q42997987-81B2E91E-11D5-40BF-B4F3-87E4CF98F029

P356

GUT.2010.208413

P1433

P1476

Liver dysfunction related to h ...... with immunosuppressive therapy

@en

P2093

A Abad

http://www.w3.org/2001/XMLSchema#string

A Gutiérrez

http://www.w3.org/2001/XMLSchema#string

C Loras

http://www.w3.org/2001/XMLSchema#string

C Saro

http://www.w3.org/2001/XMLSchema#string

D Ginard

http://www.w3.org/2001/XMLSchema#string

E Domenech

http://www.w3.org/2001/XMLSchema#string

F González-Huix

http://www.w3.org/2001/XMLSchema#string

GETECCU (Grupo Español de Enfermedades de Crohn y Colitis Ulcerosa) Group

http://www.w3.org/2001/XMLSchema#string

I Pascual

http://www.w3.org/2001/XMLSchema#string

J Barrio

http://www.w3.org/2001/XMLSchema#string

P304

1340-1346

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/GUT.2010.208413

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

59

http://www.w3.org/2001/XMLSchema#string

P50

Fernando Fernández-Bañares

Javier P Gisbert

Guillermo Bastida

María Chaparro

P577

2010-06-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20577000

http://www.w3.org/2001/XMLSchema#string